Halozyme Therapeutics | HALO - Debt


Halozyme Therapeutics reported $1.51B in Debt for its fiscal quarter ending in September of 2025.





Debt Change Date
Acadia Pharmaceuticals USD 54.81M 1.48M Sep/2025
Agios Pharmaceuticals USD 44.52M 4.24M Sep/2025
Alnylam Pharmaceuticals USD 1.31B 11.39M Sep/2025
Amarin USD 0 0 Mar/2025
Amgen USD 54.59B 1.62B Sep/2025
Baxter International USD 9.71B 13M Sep/2025
Cara Therapeutics USD 0 0 Mar/2025
Cytokinetics USD 1.2B 338.79M Sep/2025
DBV Technologies USD 8.59M 295K Sep/2025
Eli Lilly USD 42.51B 2.6B Sep/2025
Esperion Therapeutics USD 262.92M 1.76M Sep/2024
Halozyme Therapeutics USD 1.51B 1.66M Sep/2025
Intrexon USD 0 13.82M Jun/2024
Ionis Pharmaceuticals USD 2.33B 1.1B Dec/2025
MannKind USD 119.91M 73.09M Sep/2025
Minerva Neurosciences USD 0 0 Sep/2024
Nektar Therapeutics USD 0 0 Jun/2022
Pfizer USD 60.85B 78M Sep/2025
Rigel Pharmaceuticals USD 59.69M 90K Jun/2024
United Therapeutics USD 200M 100M Mar/2025
Vanda Pharmaceuticals USD 4.96M 4.96M Dec/2024